- Home
- AGEN
AGEN
Agenus Inc.
as 05-10-2024 4:00pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 274.4M | IPO Year: | 2000 |
| Target Price: | $116.50 | AVG Volume (30 days): | 810.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.78 - $42.60 | Next Earning Date: | 05-07-2024 |
| Revenue: | $161,416,000 | Revenue Growth: | 69.94% |
| Revenue Growth (this year): | 24.97% | Revenue Growth (next year): | 4.02% |
Share on Social Networks:
Stock Insider Trading Activity of Agenus Inc. (AGEN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ARMEN GARO H | AGEN | See Remarks | Feb 15 '24 | Buy | $0.65 | 500,000 | $324,050.00 | 625,969 | SEC Form 4 |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
Simply Wall St.
4 days ago
Agenus First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
4 days ago
Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Motley Fool
4 days ago
Agenus (AGEN) Q1 2024 Earnings Call Transcript
MT Newswires
4 days ago
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
MT Newswires
5 days ago
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
Zacks
5 days ago
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
GuruFocus.com
5 days ago